Navigation Links
Fostamatinib proven to be safe but not effective
Date:1/27/2011

In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied. In contrast to the prior study, however, fostamatinib was not effective in this group of patients, although the drug did appear to be safe. Results of this phase II trial are published in the February issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

Patients with RA experience inflammation, pain and swelling of their joints that often limits daily activities and can lead to permanent disability. The National Arthritis Data Workgroup estimates that 1.3 million (0.6%) of adults in the U.S. have RA, affecting two to three times as many women as men. While many RA patients are successfully treated with disease-modifying anti-rheumatic drugs (DMARDs), those with moderate to severe RA may find that newer biologically-based therapies that inhibit cytokine activity, block T cell stimulation, or modify B cell biology slow disease progression, especially when combined with methotrexate (MTX). However, there remains a subgroup of the RA patient population who do not respond to DMARDs or current biologic therapies.

The three-month double-blind, placebo-controlled trial of R788, led by Mark Genovese, M.D., from Stanford University, enrolled 219 patients with active RA who failed to respond to one or more biologic therapies (TNF inhibitor, anakinra, abatacept, or rituximab). Patients were randomly assigned in a 2:1 ratio to receive 100 mg of R788 or placebo, respectively. Efficacy and safety were evaluated over three months. Researchers evaluated changes in the disease activity score (DAS); inflammation and joint damage were assessed by MRI.

"Our findings did not find an overall difference in efficacy between the small molecule drug, R788, and placebo," noted Dr. Genovese. "However, the drug was well tolerated and clinical benefit was found in only a subset of RA patients." Results showed that the primary outcome, the ACR 201 response, as well as the ACR 50 and 70 responses, were not significantly different between the group receiving R788 and the placebo group. However, in patients who entered the trial with an elevated C-reactive protein (CRP) level, analysis suggested a meaningful difference in the ACR 20 responses between the R788 (42%) and placebo (26%) groups. Additionally MRI results demonstrated improvement in joint inflammation in those patients with the greatest disease activity.

Researchers found that the 100mg dosage of R788 was well tolerated, with the most common adverse effects being nausea and diarrhea. "We found that 100mg of R788 was a tolerable dose for chronic administration in RA," concluded Dr. Genovese. "Phase III trials of R788 need to replicate our findings and identify subpopulations most likely to respond to this novel therapy."


'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Age 50 as mammography screening threshold proven unfounded
2. United Nations Foundation Commends G8 Leaders for Accelerating Support for Proven Interventions to Improve Women's and Children's Health
3. Little Known Proven Strategy to Increase Retirement Income by 25% or More to Be Revealed in Free Webinar Thursday, June 24
4. Use of unproven mammography tool soars with Medicare coverage
5. Dana-Farber/Provenge: Approval of prostate cancer immunotherapy-new era of cancer treatments
6. Online Body Transformation Contest Proven to be a Life Changer
7. Roll-out of proven HIV/STD risk-reduction intervention with teens by community groups successful
8. Webinar Shares Proven Social Media Approach to BtoB Lead Generation
9. Biologic Joint Reconstruction Using Stem Cells Proven Successful In Patients With Arthritis
10. The Power of James Bond Symbols Proven by Dr. Emoto
11. Certified Organic Biosecur™ Product Line Proven Effective Against Foodborne Pathogens Responsible For $152 Billion in Annual Health-Related Expenses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
(Date:6/24/2016)... Gilbert, Arizona (PRWEB) , ... June 24, 2016 ... ... Gilbert-based practice, is supporting the upcoming 2016 Miss Arizona pageant as its official ... primarily serves Scottsdale, Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology: